Search Results

ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04

South Korea Plans to Establish Radioisotope Commercialization Company, Targeting Trial Production in 2028

According to sources inside and outside the South Korean government on July 31, Korea Hydro & Nuclear Power (KHNP) and relevant departments including the Ministry of Economy and Finance plan to discuss the establishment of a special purpose company (SPC) for radioisotope commercialization. The company is proposed to be set up as a subsidiary of KHNP, with domestic private enterprises, including pharmaceutical companies, expected to participate in investment. Under the current plan, the South Korean government will determine the specific investment structure and business plan through inter-departmental consultations this year, and strive to complete the company's establishment by 2027. Subsequently, the relevant parties will push forward facility construction to produce radioisotopes using nuclear power plants, with the goal of commencing trial production in 2028. Radioisot...

2026-08-01

U.S. Research Team Tracks Main Drivers of Global Methane Rise Using Stable Isotope Analysis

A research team from the U.S. National Oceanic and Atmospheric Administration Global Monitoring Laboratory and the University of Colorado has recently traced the sources of the rapid rise in global atmospheric methane since 2007 through high-precision methane concentration measurements and carbon and hydrogen stable isotope analysis. The findings show that over the past two decades, microbial emissions have been the primary factor driving the increase in methane concentrations, while fossil fuel-related methane emissions may have remained relatively stable overall. A methane molecule consists of one carbon atom and four hydrogen atoms, and methane from different sources differs in its carbon and hydrogen isotope composition. Researchers used this chemical fingerprint to distinguish methane sources: fossil fuel methane such as natural gas typically contains a relatively higher proportion of carbon-13, while methane produced by microbial processes in wetlands, landfills, livestock, and agricultural environments has a lower carbon-13 proportion, exhibiting a "lighter" isotopic signature. The proportion of deuterium in hydrogen isotopes also varies with the way methane is formed, providing a further basis for source identification.

2026-07-31

TerraPower Isotopes to Donate Actinium-225 via Oncidium Foundation to Support Cancer Treatment Accessibility

TerraPower Isotopes (TPI), a subsidiary of U.S. nuclear innovation company TerraPower, announced on July 29 that it will coordinate the donation of the rare medical isotope actinium-225 (Ac-225) through the Oncidium Foundation to support economically disadvantaged cancer patients in accessing targeted radionuclide therapy. The Oncidium Foundation is a non-profit organization dedicated to promoting global access to targeted radionuclide cancer treatments. Its RLT-Connect program aims to help financially challenged patients access relevant therapies, reducing treatment disparities caused by geographic and economic conditions. This donation also marks TPI's entry into Oncidium's collaborative ecosystem of radioisotope suppliers, medical practitioners...

2026-07-30

Ontario Invests Additional $4.6 Million in McMaster Nuclear Reactor to Expand Medical Isotope Production Capacity

The Government of Ontario, Canada, recently announced an additional investment of $4.6 million in the McMaster Nuclear Reactor to expand the production capacity of life-saving medical isotopes, supporting more cancer patients in accessing the critical radioisotopes needed for diagnosis and treatment. From left to right: Josip Zikic, Chief Nuclear Officer at McMaster University; Nolan Quinn, Minister of Colleges and Universities, Research Excellence and Security; Stephen Lecce, Minister of Energy and Mining; Susan Tighe, President and Vice-Chancellor of McMaster University; and Victor Fedeli, Minister of Economic Development, Job Creation and Trade. (Georgia Kirkos/McMaster University) This investment builds on a previous $18 million...

2026-07-30

Urenco Isotopes Collaborates on EMIS Test Facility to Strengthen Europe's Enriched Lanthanide Isotope Supply Chain

On July 28, 2026, Urenco Isotopes announced a collaboration with RI Research Instruments to advance the construction of a dedicated Electromagnetic Isotope Separation (EMIS) test facility, aiming to strengthen the future European supply chain for enriched lanthanide elements and meet the growing demand for high-purity stable isotopes in scientific research and potential medical isotope applications. Lanthanides are rare earth metals, and their isotopes may be used in the future for cancer diagnosis and treatment. Currently, reliable sources of high-purity lanthanide stable isotopes remain limited, with the supply chain concentrated among a few producers, and Europe's local supply capacity is relatively insufficient. Under the collaboration arrangement, RI Research Instruments...

2026-07-29

China and Russia Discuss Cooperation on Non-Energy Applications of Nuclear Technology in Beijing

On July 24, Rosatom hosted a Russian-Chinese business matchmaking event in Beijing, focusing on cooperation in the non-energy applications of nuclear technology. Held at the Trade Representation of the Russian Federation in China, the event was attended b

2026-07-27

CNNC achieves end-to-end process integration for the production of the medical isotope Terbium-161.

Recently, the China Institute of Atomic Energy (CIAE) under the China National Nuclear Corporation (CNNC) successfully established the entire production process for the emerging medical isotope Terbium-161 (161Tb), producing a 100-millicurie, high-purity

2026-07-27